Welcome to our dedicated page for Innoviva SEC filings (Ticker: INVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Innoviva, Inc. (NASDAQ: INVA) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Forms 10-K, 10-Q, 8-K, and other documents filed with the U.S. Securities and Exchange Commission. Innoviva is a diversified healthcare holding company with a royalties portfolio linked to GSK respiratory products, a critical care and infectious disease platform operated through Innoviva Specialty Therapeutics, and a portfolio of strategic healthcare investments.
In its SEC reports, Innoviva discusses royalty revenue from RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, net product sales from therapies such as GIAPREZA®, XERAVA®, XACDURO®, and ZEVTERA®, and the performance of its strategic investment portfolio. Current reports on Form 8-K, for example, furnish quarterly earnings press releases that detail revenue composition, income from operations, changes in fair values of equity and long-term investments, and balance sheet metrics.
For investors following Innoviva’s infectious disease and critical care focus, periodic filings also provide context on regulatory milestones and development programs, such as the New Drug Application for zoliflodacin and its QIDP designation. Proxy statements and related documents can offer additional insight into governance, equity compensation, and capital allocation policies, while registration statements and prospectuses may describe financing activities.
On Stock Titan, each Innoviva filing is accompanied by AI-powered summaries designed to highlight key points, such as changes in royalty streams, trends in IST net product sales, significant investments or licensing transactions, and updates to risk factors. Users can quickly scan recent 10-Q and 10-K reports, review 8-K announcements, and examine Form 4 insider transaction filings to understand how executives and directors are trading INVA shares. Real-time integration with EDGAR helps ensure that new Innoviva filings appear promptly, while AI-generated overviews make dense regulatory documents more accessible to both individual and professional investors.
Innoviva reported strong growth for 2025, with total revenue rising to
The core royalties portfolio generated
Innoviva, Inc. filed its annual report outlining its evolution from a pure royalty business into a diversified biopharmaceutical company. It earns royalties from GSK’s respiratory drugs RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, with tiered rates up to 15% of global net sales.
The company now runs a hospital-focused critical care and infectious disease platform anchored by five FDA-approved products: GIAPREZA®, XACDURO®, XERAVA®, ZEVTERA® and NUZOLVENCE®. These treat severe conditions such as septic shock, carbapenem-resistant Acinetobacter infections, complicated intra-abdominal infections, serious bacterial pneumonias and uncomplicated gonorrhea.
Innoviva highlights regulatory exclusivity, including QIDP designations and extended market protection periods, and notes active competition from numerous branded and generic antibiotics. It also emphasizes disciplined capital deployment, strategic stakes in other healthcare companies and a strategy focused on high unmet medical needs.
Innoviva, Inc. Chief Financial Officer Stephen Basso reported a tax-related share disposition. On February 20, 2026, 1,244 shares of common stock were withheld by the company at $23.39 per share to satisfy income tax obligations on vesting equity awards. After this withholding, Basso directly owns 50,013 shares of Innoviva common stock.
Innoviva, Inc. Chief Executive Officer Pavel Raifeld reported a tax-related share disposition. On the vesting of previously granted equity, 2,986 shares of common stock were withheld by the company at $23.39 per share to cover income tax obligations. After this withholding transaction, Raifeld directly owned 159,290 shares of Innoviva common stock.
Innoviva, Inc. Chief Accounting Officer Marianne Zhen reported a routine tax-related share disposition. On February 20, 2026, 2,460 shares of common stock were withheld at
Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation reported a significant ownership stake in Innoviva, Inc. common stock. As of 12/31/2025, they beneficially owned 4,210,172 shares, representing 5.63% of the outstanding common stock, with sole voting and dispositive power over these shares.
The firms state the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Innoviva. Certain funds managed by Renaissance Technologies LLC have the right to receive dividends and sale proceeds from these shares.
Dimensional Fund Advisors LP has filed an amended Schedule 13G reporting beneficial ownership of 4,360,401 shares of Innoviva Inc. common stock, representing 5.8% of the class as of 12/31/2025. Dimensional reports sole voting power over 4,255,642 shares and sole dispositive power over 4,360,401 shares.
The shares are held by a series of funds and accounts it advises or manages, and Dimensional states that all securities are owned by these funds. Dimensional disclaims beneficial ownership of the securities beyond what is required for Section 13(d) reporting. It also certifies that the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Innoviva.
Innoviva, Inc. (INVA) reported insider equity activity for its Chief Financial Officer, Stephen Basso, on a Form 4. On November 15, 2025, he acquired 604 shares of common stock at $0 under the Innoviva Employee Stock Purchase Plan. On November 20, 2025, 237 shares of common stock were withheld by Innoviva at $21.16 per share to cover income tax obligations tied to the quarterly vesting of previously granted equity awards. After these transactions, he directly owned 51,257 shares of Innoviva common stock.
Innoviva, Inc. (INVA)11/20/2025, 992 shares of common stock were withheld by Innoviva at a price of $21.16 per share to cover income tax obligations tied to the quarterly vesting of previously granted employee equity awards. After this withholding, the reporting person beneficially owned 48,337 shares of Innoviva common stock directly.
Innoviva, Inc. (INVA) reported an insider equity award. The company’s Chief Financial Officer filed a Form 4 showing acquisition of 27,609 shares of common stock on 11/03/2025 at $18.11 per share, bringing holdings to 50,890 shares directly.
The award is a time-vested RSU: 25% vests on November 20, 2026, with the remainder vesting in 12 substantially equal quarterly installments thereafter, subject to continued service. Vesting may accelerate upon a qualifying change in control or an involuntary termination within 24 months following such a change, as approved by the Board’s Compensation Committee.